Login to Your Account

Shire, Yes; Pfizer, Maybe

Genzyme Could Get 'ERT' as Pharma Makes Gaucher Bids

By Jennifer Boggs

Thursday, November 5, 2009
As Shire plc gears up for an early 2010 PDUFA date for its enzyme replacement therapy velaglucerase alfa in Gaucher's disease, potential competitor Protalix BioTherapeutics Inc. reportedly is being eyed by pharma giant Pfizer Inc. for a possible collaboration or even outright acquisition. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription